González ÁC, Muñoz JG

Language: Spanish
References: 24
Page: 629-635
PDF size: 438.74 Kb.

ABSTRACT

In recent years, a new mechanism involved in the pathophysiology of type 2 diabetes has been recognized: the shortfall in production and / or action of incretins. Incretins are gut hormones that stimulate insulin secretion in response to nutrient intake. Glucagon-like peptide 1 (GLP1) and glucosedependent insulinotropic peptide (GIP) are major incretins discovered until today. Both also exhibit trophic effect on beta cells of pancreatic islets. GLP-1 has other actions such as the inhibition of glucagon secretion, slowing gastric emptying and inhibition of appetite. Both incretins are rapidly degraded by the enzyme dipeptidyl peptidase 4 (DPP-4). New drugs such as GLP-1 analogs and the DPP- 4 inhibitors are promising as treatment for patients with type 2 diabetes.

REFERENCES

1. Memoria Institucional Ministerio Salud, 2009.

2. Rother KI. Diabetes Treatment: Bringing the divide. N Engl J Med. 2007;15: 1499-1501.

3. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004; 27: 17-20.

4. UK Prospective Diabetes Study Group. Overview of 6 year´s terapy of type II diabetes: a progressive disease. Diabetes. 1995; 44: 1249- 1258.

5. Valverde A. El GLP-1, incretina antidiabética con potencial terapéutico. Diabetol. 2001; 17:191- 198. 635

6. Drucker D J. Enhancing Incretin Action for the Treatment of Type 2 Diabetes. Diabetes Care. 2003; 10 (26):2929-40.

7. Camilleri M. Diabetic Gastroparesis. N Engl J Med. 2007; 356:820-9

8. Guyton, C.G. and Hall, J.E. Tratado de Fisiología Médica. 11ª Edición. Elsevier, 2006.

9. Fauci AS, Braunwald E, Kasper DL, Longo DL, Hauser SL, Loscalzo J. Harrison: Principios de Medicina Interna. Mcgraw-Hill. 17ª edición. 2009.

10. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009; 94(6) 1843-1852.

11. Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleveland Clinic Journal of Medicine. 2009; 76(5): S12-S19.

12. Brown DX, Evans M. Choosing between GLP-1 Receptor Agonist and DPP-4 Inhibitors: A Pharmacological Perspective. Journal of Nutrition and Metabolism. 2012: 1-10.

13. Golderberg RM. Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents. Canadian Journal of Diabetes. 2011; 35 (5): 518-527.

14. Cobble M. Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetology and Metabolic Syndrome. 2012; 4: 1-10.

15. Harshal P, Firas Al Badarin, Hamza Al Shami, Salman B. Meta-analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. Am J Cardiol. 2012; 110: 826-833.

16. Barnett AH . Lixisenatide : Evidence for its potencial use in treatment of type 2 diabetes.Dove Press Journal (Core evidence)2011:6 67 -79.

17. Rather RE,Rosenstock J,Bokat G.Original Article:Treatment Dose- dependent effects of the once daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin:a randomized double- blind,placebo-controlled trial. DIABETICMedicine.2010

18. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011; 378: 182 -197.

19. Berlie H, Hurren KM, Pinelli NR. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2012:5 165 – 164.

20. Werner U, Haschke G, Herlin AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory peptides 164 (2010) 58- 64.

21. Christensen M, Knop FK,Holst JJ,Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs.2009;12(8):503 -513.

22. Seino Y,Min KW,Niemoeller E,Takami A. Randomized, double- blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea. Diabetes, Obesity and Metabolism 2012; 10 (14): 910–917.

23. Buse J, Rosenstock J, Sesti G, Schmidt W et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: 26 week randomized, parallel-group, multinational, open- label trial (LEAD-6). Lancet. 2009; 374: 39-47.

24. Inzuchi SE, Bergenstal RM, Buse JB, Diamant M et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetología . 2012.